Clinician reference tool — not medical advice. This is a clinical decision-aid intended for healthcare professionals: it gives deterministic suggestions to think with, not a diagnosis or a prescription. If you’re a patient, you’re welcome to look around — but please review anything here with your own doctor; it isn’t a substitute for personalized medical care.
Reference tool — not medical advice. Deterministic suggestions to think with, grounded in current guidelines and Health Canada product monographs; clinician judgement, current monographs, and live public-formulary coverage always required. Runs entirely in your browser — no data is collected.

Evidence: CADDRA ADHD Medication Chart (bilingual, Canada-wide) — m… 2026 · sources last checked 2026-08-20

ADHD medication selector

Pick the age band and patient characteristics to get ranked suggestions across the Health Canada-approved ADHD agents — with the guideline reasoning and references behind each.

Age band — select to begin

Select an age band above to begin.

Guidelines cited

References

  1. [1]CADDRA (Canadian ADHD Resource Alliance). Canadian ADHD Practice Guidelines, 4.1 Edition, January 2021. link
  2. [2]CADDRA ADHD Medication Chart (bilingual, Canada-wide) — most current edition, 2026. link
  3. [3]National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management (NG87). Published 14 March 2018; last exceptional surveillance review 7 May 2025. link
  4. [4]Wolraich ML, et al. (American Academy of Pediatrics). Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics 2019;144(4):e20192528. link
  5. [5]Canadian Paediatric Society. ADHD in children and youth: Part 1 — Etiology, diagnosis, and comorbidity. Paediatr Child Health 2018;23(7):447. link
  6. [6]Canadian Paediatric Society. ADHD in children and youth: Part 2 — Treatment. Paediatr Child Health 2018;23(7):462. link
  7. [7]Canadian Paediatric Society. ADHD in children and youth: Part 3 — Assessment and treatment with comorbid ASD, ID, or prematurity. Paediatr Child Health 2018;23(7):485. link
  8. [8]Health Canada — Drug Product Database & product monographs (Concerta, Biphentin, Foquest, Ritalin/Ritalin SR, Vyvanse, Dexedrine, Adderall XR, Strattera, Intuniv XR). link
  9. [9]Kooij JJS, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry 2019;56:14 (European Network Adult ADHD). link
  10. [10]Ontario Drug Benefit (ODB) e-Formulary — Limited Use criteria for ADHD stimulants (failure/intolerance/contraindication to first agent, misuse-risk, or pediatrician/psychiatrist-recommended). Check live before counselling on coverage. link
  11. [11]Health Canada Drug and Health Products Portal — Summary Basis of Decision, FOQUEST (methylphenidate MLR capsules): adult approval 2017, pediatric/adolescent extension 2019, ~16h duration of action. link
  12. [12]Health Canada Drug and Health Products Portal — Summary Basis of Decision, INTUNIV XR (guanfacine ER): approved ages 6-17 only in Canada, no adult indication. link
  13. [13]Manitoba Health drug-shortage PIN list (national CDA shortage reporting) — Adderall XR shortage entries across multiple strengths, updated to June 2026. Confirm current status before prescribing. link